Hormonal Changes During Perimenopause: What the Evidence Shows

Perimenopause is frequently misunderstood as a brief prelude to menopause, yet the hormonal changes involved can span a decade or more and touch nearly every organ system. Estrogen and progesterone do not simply decline in a straight line; they fluctuate in ways that can be disorienting and difficult to attribute to a single cause. Grasping the nature and scope of these hormonal shifts is essential for understanding why this transition carries such significant long-term health implications.

Created with AI

According to Dr. Jessica Shepherd, perimenopause typically starts in the late 30s and continues through the 40s, far earlier than most women expect. Rather than a sudden drop, the transition is characterized by years of hormonal fluctuation in which estrogen and progesterone levels rise and fall unpredictably. Dr. Shepherd describes this as a "dimmer switch" phase: estrogen gradually declines overall, but the path is irregular, which is why symptoms can appear inconsistent or confusing.

Data presented at menopause conferences, drawn from a retrospective analysis of 120 million women, suggests perimenopause can begin as early as age 35, with an average onset around age 45. The same analysis notes that by ages 35 to 40, women lose less than 1% of their eggs, yet this is sufficient to meaningfully reduce estrogen production. The implication is that hormonal change begins earlier than clinical symptoms might suggest, making awareness of the timeline important for timely intervention.

Created with AI

One of the most important reframings in understanding perimenopause is recognizing that estrogen is not confined to reproductive function. According to Dr. Shepherd, estrogen receptors are distributed throughout the body, including in muscles, the gut, the heart, the brain, and bones. When estrogen declines, the effects are therefore systemic rather than localized.

The analysis of 120 million women referenced above characterizes estrogen depletion as producing a "systemic inflammatory state," precisely because receptors on every tissue are affected. Dr. Shepherd further notes that estrogen is a potent anti-inflammatory hormone, and its loss may help explain the parabolic spike in autoimmune disease observed in women during their 40s and 50s. Chronic stress and inflammation, combined with estrogen loss, are described as creating conditions that make the body more vulnerable to autoimmune conditions.

Created with AI

While estrogen tends to receive the most attention, progesterone decline is also a significant feature of perimenopause. According to source material from Dr. Stacy Sims, disrupted sleep during perimenopause is partly attributable to progesterone decline, which in turn affects nighttime restorative processes including the brain's glymphatic cleaning system. When sleep is interrupted, the brain attempts this cleaning during waking hours, which is described as one neurological basis for perimenopausal brain fog.

Testosterone is also relevant, though its role is sometimes overlooked. Dr. Sims notes that testosterone therapy can be beneficial for some women during perimenopause, particularly those under significant physiological stress, but emphasizes that this is separate from conventional menopausal hormone therapy and requires individual assessment. The 120 million women analysis similarly identifies testosterone as an essential female hormone, not merely a male one, and notes that micronized progesterone plays a specific role in protecting the endometrium during hormone therapy.

The interplay among estrogen, progesterone, and testosterone during perimenopause is therefore more complex than a simple estrogen-deficiency story. Each hormone has distinct receptor distributions and physiological roles, and their collective decline or fluctuation produces a range of effects that vary considerably between individuals.

Created with AI

Estrogen's presence in the heart and blood vessels means its decline has direct cardiovascular consequences. Dr. Shepherd explains that estrogen receptors exist throughout the heart and blood vessels, and when estrogen falls, the heart's contractility decreases while atherosclerotic plaque formation increases. This provides a biological explanation for the well-documented rise in cardiovascular disease risk after menopause.

Metabolic function is also affected. According to Dr. Shepherd, declining estrogen impairs the regulation of insulin and glucose. Muscle mass, which is the largest absorber of glucose in the body, declines at roughly 3 to 5 percent per decade, and estrogen normally helps optimize the relationship between muscle and glucose metabolism. As both estrogen and muscle mass fall together, glucose is more likely to remain in the bloodstream and convert to fat, particularly visceral fat around organs. Source material on perimenopausal weight changes notes that fat redistribution from hips and thighs to the abdominal area is a common feature of this transition, and that this visceral fat accumulation worsens insulin resistance in a self-reinforcing cycle.

On average, women gain approximately five pounds during the perimenopausal transition, with up to 20% gaining ten pounds or more, according to one source. The hormonal drivers include not only declining estrogen but also increased insulin resistance, reduced microbiome diversity, and sleep disruptions affecting roughly 60% of women during this period.

Created with AI

Bone tissue is another site where estrogen receptors play a critical role. Dr. Shepherd explains that bones rely on estrogen signaling to maintain mineral density, and as estrogen declines during perimenopause, bone loss accelerates. Over a span of decades, this can lead to fragile bones prone to fracture, a condition that progresses silently until a fracture occurs.

Dr. Stacy Sims has addressed bone density in the context of perimenopause, and the broader source material emphasizes that skeletal health during this transition is not simply a matter of calcium intake. Resistance training provides the mechanical stimulus that bones need to maintain and build density, a point that several sources converge on. The hormonal environment created by estrogen decline makes this mechanical stimulus even more important as a compensatory strategy.

Created with AI

The brain is among the organs most densely populated with estrogen and progesterone receptors. According to Dr. Stacy Sims, these receptors are found throughout brain regions including the amygdala and hippocampus. During perimenopause, declining hormone levels lead to receptor hypersensitivity in some areas and reduced activation in others, altering fear response, stress reactivity, and cognition.

This neurological disruption is one explanation for the brain fog that many women report during perimenopause. The mechanism described involves interrupted sleep, driven partly by progesterone decline and partly by nighttime hot flashes, which prevents the brain from completing its glymphatic cleaning process at night. The brain then attempts this process during waking hours, impairing cognitive function in the process. This framing positions perimenopausal brain fog not as a vague or psychosomatic complaint but as a physiologically grounded consequence of specific hormonal changes acting on specific brain systems.

The broader cognitive and emotional effects of estrogen and progesterone fluctuation during perimenopause, including mood changes and altered stress reactivity, are consistent with the receptor distribution described above. Individual variation in how these changes manifest is substantial, however, and the same hormonal shift does not produce identical neurological effects in every woman.

Created with AI

• Perimenopause may begin as early as the mid-30s and involves years of unpredictable hormonal fluctuation, not a simple linear decline in estrogen.
• Estrogen receptors are present in virtually every tissue, including the brain, heart, blood vessels, bones, muscles, and gut, meaning its decline produces systemic effects rather than isolated symptoms.
• Progesterone decline contributes independently to sleep disruption and cognitive effects, while testosterone is also considered an essential female hormone that may require attention during this transition.
• Declining estrogen impairs insulin-glucose regulation and, combined with age-related muscle loss, promotes visceral fat accumulation and worsening metabolic function.
• Bone density loss accelerates during perimenopause due to reduced estrogen signaling in skeletal tissue, making this a critical window for preventive strategies.
• Neurological effects including brain fog and altered stress reactivity have a documented hormonal basis in estrogen and progesterone receptor changes in the amygdala and hippocampus.